Loading
Everything in development, the medicines held by this cancer's subtypes, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for Marginal zone lymphoma, drawn from the whole corpus: 13 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
2 medicines on record are linked to one of the types below rather than to Marginal zone lymphoma itself. Grouped by the type that holds them; each list opens that type's own page.
Transformation to diffuse large B-cell lymphoma in a minority.
No standard sequence of therapies is proven by randomised trials.
Rare sites (lung, skin, dura) are managed by extrapolation.
Nothing recorded yet.
Also on OnCo: Find a trial · Expert centres.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 11 changes by month →When this page itself was last checked or edited.
Median investigator-assessed progression-free survival 22.
MCL and MZL indications voluntarily withdrawn after confirmatory trials missed
High objective and complete response rates in relapsed follicular lymphoma with durable remissions; accelerated approval in March 2021.
A milestone in how this cancer is treated.
Lenalidomide plus rituximab substantially lengthened progression-free survival compared with rituximab alone; approved in May 2019.